http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1869018-B1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_27a71ddaaa2f5a8c228fc6cb3f3b3098 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-422 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4196 |
| filingDate | 2006-04-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2010-01-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7ea4c4167215f6b32641d3694728b0f8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6302b7bf4bd9c5e1490cb590114d2943 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c3b89a0df7bc3f25707a51f76f9223ad http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3082372f8bd7d40e640691a840efd79a |
| publicationDate | 2010-01-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-1869018-B1 |
| titleOfInvention | 3-triazolylthioalkyl-3-azabicyclo (3 - 1 - o) hexanes and their use as dopamine d3 receptor ligands |
| abstract | The present invention relates to novel compounds of formula (I) or a pharmaceutically acceptable salt thereof: wherein • R1 is hydrogen or C1-4alkyl; • R2 is C1-4alkyl; • R3 is hydrogen, or a phenyl group, a heterocyclyl group, a 5- or 6-membered heteroaromatic group, or a 8- to 11-membered bicyclic group, any of which groups is optionally substituted by 1, 2, 3 or 4 substituents selected from the group consisting of: halogen, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, C1-4alkanoyl and SF5; • p is 0, 1 , 2, 3 or 4; and • R4 is independently selected from a group consisting of: halogen, hydroxy, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, haloC1-4alkoxy and C1-4alkanoyl; • n is 0 or 1 ; wherein when R4 is chlorine and p is 1 , such R4 is not present in the ortho position with respect to the linking bond to the rest of the molecule; and wherein, if n is 0, R3 comprises at least one SF5 group as a substituent; processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as modulators of dopamine D3 receptors, e.g. to treat drug dependency, as antipsychotic agents, to treat obsessive compulsive spectrum disorders, premature ejaculation or cognition impairment. |
| priorityDate | 2005-04-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 534.